Benzodiazepines (Nonsedative/ Hypnotics*)

Total Page:16

File Type:pdf, Size:1020Kb

Benzodiazepines (Nonsedative/ Hypnotics*) Texas Vendor Drug Program Drug Use Criteria: Benzodiazepines (Nonsedative/ Hypnotics*) Publication History 1. Developed October 1993. 2. Revised March 2020; March 2018; May 2017; December 2014; March 2013; June 2011; January 2009; April 2003; December 2001; December 2000; December 1999; November 1998; November 1997; December 1996. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document. Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage. Prepared by: Drug Information Service, UT Health San Antonio. The College of Pharmacy, The University of Texas at Austin. (*Sedative/hypnotic benzodiazepines are included in Sedative/Hypnotics criteria.) 1 1 Dosage 1.1 Adults Non-sedative/hypnotic benzodiazepines are FDA-approved for use in the outpatient setting to manage anxiety (alprazolam, chlordiazepoxide, clorazepate, oral diazepam, lorazepam, oxazepam), panic disorder (alprazolam, clonazepam), acute musculoskeletal (MS) conditions including spasticity (oral diazepam), seizures [clobazam (Lennox-Gastaut syndrome), clonazepam, clorazepate, nasal, oral and rectal diazepam], and acute alcohol withdrawal (chlordiazepoxide, clorazepate, oral diazepam, oxazepam).[1-10] The FDA has approved a new dosage formulation for clobazam, an oral film (Sympazan®), for adjunctive seizure management in Lennox-Gastaut syndrome.[11] A new diazepam nasal formulation (Valtoco®) has been FDA-approved for use in adult patients to treat intermittent frequent seizure episodes that differ from a patient’s usual seizure pattern.[12] The chlordiazepoxide-amitriptyline combination is indicated for depression with associated anxiety symptoms, while chlordiazepoxide/clidinium is FDA-approved for emotional factor control in gastrointestinal disorders as well as adjunctive use in peptic ulcer disease and irritable bowel syndrome.[13, 14] Tables 1 and 2 summarize the adult maximum recommended dosages for non-sedative/hypnotic benzodiazepines as monotherapy and combination therapy. Table 1. Adult Benzodiazepine Maximum Recommended Daily Dosages: Monotherapy[1-12] Dosage Form/ Treatment Maximum Recommended Drug Name Strength Indication Dosage alprazolam 0.25 mg, 0.5 mg, 1 (Xanax®, generics) mg, 2 mg tablets, disintegrating tablets; 0.5 mg, 1 mg, 2 anxiety < and > 65 years: 4 mg daily mg, 3 mg extended-release tablets; 1 mg/ml oral solution alprazolam < and > 65 years: 10 mg panic daily 2 Dosage Form/ Treatment Maximum Recommended Drug Name Strength Indication Dosage chlordiazepoxide alcohol 5 mg , 10 mg, 25 < and > 65 years: 300 mg (generics) withdrawal mg capsule daily, in divided doses (AW) chlordiazepoxide < 65 years: mild, moderate: 40 mg daily anxiety severe: 100 mg daily > 65 years: 20 mg daily clobazam < 65 years: (Onfi®, 10 mg, 20 mg seizures 40 mg/day in two divided generics, tablets; associated doses Sympazan®) 2.5 mg/mL with > 65 years: suspension; 5 mg, Lennox- 20 mg/day in two divided 10 mg, 20 mg Gastaut doses (weights < 30 kg) oral soluble film syndrome 40 mg/day in two divided doses (weights > 30 kg) clonazepam 0.5 mg, 1 mg, 2 (Klonopin®, mg tablets; generics) 0.125 mg, 0.25 panic < and > 65 years: 4 mg daily mg, 0.5 mg, 1 mg, 2 mg disintegrating tablets clonazepam < and > 65 years: 20 mg seizures daily clorazepate 3.75 mg, 7.5 mg, < and > 65 years: 90 mg (Tranxene®, AW 15 mg tablets daily generics) clorazepate < and > 65 years: 60 mg anxiety daily clorazepate < and > 65 years: 90 mg seizures daily diazepam 28-50 kg^: 10 mg as one (nasal) spray in one nostril (Valtoco®) 5 mg as one 5 mg (equates to 0.2 mg/kg device, 10 mg as dose) one 10 mg 51-75 kg^: 15 mg as 2 x device, 15 mg as 7.5 mg devices with one 2 x 7.5 mg seizures spray in each nostril devices, 20 mg (equates to 0.2 mg/kg as 2 x 10 mg dose) devices nasal > 76 kg^: 20 mg as 2 x 10 liquid mg devices with one spray in each nostril (equates to 0.2 mg/kg dose) 3 Dosage Form/ Treatment Maximum Recommended Drug Name Strength Indication Dosage diazepam (oral) 2 mg, 5 mg, 10 mg (Valium®, oral tablets; < and > 65 years: 40 mg AW generics) 5 mg/mL, 5 mg/5 daily mL oral solution diazepam (oral) < and > 65 years: 40 mg anxiety daily diazepam (oral) musculoskeleta < and > 65 years: 40 mg l conditions daily diazepam (oral) < and > 65 years: 40 mg seizures daily diazepam < and > 65 years: (rectal) 2.5 mg, 10 mg, 20 0.2 mg/kg; may be repeated seizures (Valium®, mg rectal gel once 4-12 hours after initial generics) dose lorazepam 0.5 mg, 1 mg, 2 < and > 65 years: 10 mg (Ativan®, mg tablets; anxiety daily, in divided doses generics) 2 mg/mL solution oxazepam < 65 years: 120 mg daily in (Serax®, 10 mg, 15 mg, 30 divided doses AW generics) mg capsule > 65 years: 60 mg daily in divided doses# oxazepam < 65 years: mild, moderate: 60 mg daily in divided doses anxiety severe: 120 mg daily in divided doses > 65 years: 40 mg daily in divided doses *benzodiazepine doses should be reduced to lowest effective dose, if possible, in elderly (patients > 65 years of age), to minimize oversedation; these patients more sensitive to pharmacologic effects of these agents +Dose rounded up to nearest commercially available dose (in multiples of 2.5 mg); should not be administered by caregivers outside the hospital more frequently than one course every 5 days with a maximum of 5 courses per month; not for chronic administration to minimize potential for development of tolerance #in elderly patients, doses up to 120 mg/day may be needed to treat AW ^may give second diazepam nasal dose at least 4 hours after first dose, if necessary; may not use more than 2 doses to treat single episode; may not treat more than 1 episode/5 days or more than 5 episodes/month 4 Table 2. Adult Benzodiazepine Maximum Recommended Dosages: Combination Therapy[1-7, 13, 14] Maximum Dosage Form/ Treatment Drug Name Recommended Strength Indication Dosage chlordiazepoxide/ 5 mg/12.5 mg 60 mg amitriptyline tablets depression with chlordiazepoxide (Limbitrol®, 10 mg/25 mg concurrent / 150 mg generics) double- anxiety amitriptyline strength symptoms daily in divided tablets doses chlordiazepoxide/ emotional/ clidinium somatic factors (Librax®, in gastro- generics) intestinal disorders; 40 mg/20 mg per 5 mg/ 2.5 mg adjunctive day (2 capsules 4 capsule therapy in times daily) peptic ulcer disease or irritable bowel syndrome 1.2 Pediatrics Safety and effectiveness of alprazolam and combination therapies, chlordiazepoxide/amitriptyline and chlordiazepoxide/clidinium, in children less than 18 years of age have not been established.[1-5, 9, 13, 14] Clobazam has recently been approved in children 2 years of age and older to manage seizures associated with Lennox-Gastaut syndrome.[1-5, 10] The FDA has approved a new dosage formulation for clobazam, an oral film (Sympazan®), for adjunctive seizure management in Lennox-Gastaut syndrome in patients 2 years and older.[11] A new diazepam nasal formulation (Valtoco®) has been FDA-approved for use in patients 6 years and older to treat intermittent frequent seizure episodes that differ from a patient’s usual seizure pattern.[12] With the exception of alprazolam, non-sedative/hypnotic benzodiazepines are indicated for use in pediatric patients to manage anxiety or seizures. Pediatric dosages and age limitations for benzodiazepines are summarized in Table 3. 5 Table 3. Pediatric Benzodiazepine Maximum Recommended Dosages[1-12] Treatment Drug Name Maximum Recommended Dosage Indication chlordiazepoxide alcohol adolescents > 12 years: 300 mg daily in divided withdrawal (AW) doses chlordiazepoxide anxiety > 6 years: 30 mg daily in divided doses clobazam seizures 2 years and older, adolescents < 30 kg: 20 associated with mg/day in two divided doses Lennox-Gastaut 2 years and older, adolescents > 30 kg: 40 syndrome mg/day in two divided doses clonazepam < 10 years or < 30 kg: 0.2 mg/kg daily in divided doses seizures > 10 years or > 30 kg: 20 mg daily in divided doses clorazepate 9-12 years: 60 mg daily in divided doses seizures > 12 years: 90 mg daily in divided doses diazepam 6-11 years of age: (nasal) 10-18 kg: 5 mg as one spray in one nostril (equates to 0.3 mg/kg dose) 19-37 kg^: 10 mg as one spray in one nostril (equates to 0.3 mg/kg dose) 38-55 kg^: 15 mg as 2 x 7.5 mg devices with one spray in each nostril (equates to 0.3 mg/kg dose) 56-74 kg^: 20 mg as 2 x 10 mg devices with one spray in each nostril (equates to 0.3 mg/kg dose) seizures > 12 years of age: 14-27 kg: 5 mg as one spray in one nostril (equates to 0.2 mg/kg dose) 28-50 kg^: 10 mg as one spray in one nostril (equates to 0.2 mg/kg dose) 51-75 kg^: 15 mg as 2 x 7.5 mg devices with one spray in each nostril (equates to 0.2 mg/kg dose) > 76 kg^: 20 mg as 2 x 10 mg devices with one spray in each nostril (equates to 0.2 mg/kg dose) diazepam (oral) > 6 months of age: 10 mg/day in divided doses musculoskeletal have been used; dose may be increased as needed conditions and tolerated – no maximum dose documented diazepam (oral) > 6 months of age: 10 mg/day in divided doses seizures have been used; dose may be increased as needed and tolerated – no maximum dose documented diazepam 2-5 years: 0.5 mg/kg/dose (rectal) seizures+ 6-11
Recommended publications
  • Understanding Benzodiazephine Use, Abuse, and Detection
    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
    [Show full text]
  • Table 6.12: Deaths from Poisoning, by Sex and Cause, Scotland, 2016
    Table 6.12: Deaths from poisoning, by sex and cause, Scotland, 2016 ICD code(s), cause of death and substance(s) 1 Both Males Females ALL DEATHS FROM POISONING 2 1130 766 364 ACCIDENTS 850 607 243 X40 - X49 Accidental poisoning by and exposure to … X40 - Nonopioid analgesics, antipyretics and antirheumatics Paracetamol 2 1 1 Paracetamol, Cocaine, Amphetamine || 1 0 1 X41 - Antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified Alprazolam, MDMA, Cocaine || Cannabis, Alcohol 1 1 0 Alprazolam, Methadone || Pregabalin, Tramadol, Gabapentin, Cannabis 1 1 0 Alprazolam, Morphine, Heroin, Dihydrocodeine, Buprenorphine || Alcohol 1 1 0 Alprazolam, Oxycodone, Alcohol || Paracetamol 1 0 1 Amitriptyline, Cocaine, Etizolam || Paracetamol, Codeine, Hydrocodone, Alcohol 1 1 0 Amitriptyline, Dihydrocodeine || Diazepam, Paracetamol, Verapamil, Alcohol 1 1 0 Amitriptyline, Fluoxetine, Alcohol 1 0 1 Amitriptyline, Methadone, Diazepam || 1 1 0 Amitriptyline, Methadone, Morphine, Etizolam || Gabapentin, Cannabis, Alcohol 1 1 0 Amitriptyline, Venlafaxine 1 0 1 Amphetamine 1 1 0 Amphetamine || 1 1 0 Amphetamine || Alcohol 1 1 0 Amphetamine || Chlorpromazine 1 1 0 Amphetamine || Fluoxetine 1 1 0 Amphetamine, Dihydrocodeine, Alcohol || Procyclidine, Tramadol, Duloxetine, Haloperidol 1 0 1 Amphetamine, MDMA || Diclazepam, Cannabis, Alcohol 1 1 0 Amphetamine, Methadone || 1 1 0 Amphetamine, Oxycodone, Gabapentin, Zopiclone, Diazepam || Paracetamol, Alcohol 1 0 1 Amphetamine, Tramadol || Mirtazapine, Alcohol 1 1 0 Benzodiazepine
    [Show full text]
  • XANAX® Alprazolam Tablets, USP
    XANAX® alprazolam tablets, USP CIV WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death [see Warnings, Drug Interactions]. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. DESCRIPTION XANAX Tablets contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-α] [1,4] benzodiazepine. The structural formula is represented to the right: Alprazolam is a white crystalline powder, which is soluble in methanol or ethanol but which has no appreciable solubility in water at physiological pH. Each XANAX Tablet, for oral administration, contains 0.25, 0.5, 1 or 2 mg of alprazolam. XANAX Tablets, 2 mg, are multi-scored and may be divided as shown below: 1 Reference ID: 4029640 Inactive ingredients: Cellulose, corn starch, docusate sodium, lactose, magnesium stearate, silicon dioxide and sodium benzoate. In addition, the 0.5 mg tablet contains FD&C Yellow No. 6 and the 1 mg tablet contains FD&C Blue No. 2. CLINICAL PHARMACOLOGY Pharmacodynamics CNS agents of the 1,4 benzodiazepine class presumably exert their effects by binding at stereo specific receptors at several sites within the central nervous system. Their exact mechanism of action is unknown. Clinically, all benzodiazepines cause a dose-related central nervous system depressant activity varying from mild impairment of task performance to hypnosis.
    [Show full text]
  • Drug Names That Are Too Close for Comfort
    MEDICATION SAFETY Drug Names That Are Too Close for Comfort and therefore at risk of “seeing” prescriptions for the newer product clobazam as the more familiar clonazePAM. Use TWO IDENtifieRS at THE POS Within the span of a couple of days, the Institute for Safe Medication Practices received two more reports of wrong patient errors at the point-of-sale. Both were submitted by the parents of the patients involved. In one event, a teenager, who Look- and sound-alike similarity between the official names was supposed to receive methylphenidate for Attention Deficit clobazam (ONFI) and clonazePAM (KLONOPIN) has led Hyperactivity Disorder (ADHD), was given a cardiac drug to several reports expressing concern that patients may in- intended for a different patient. The mother who was picking advertently receive the wrong medication in either hospital up the prescription for her son caught the error because or outpatient settings. The drugs share similar indications, the pharmacist mentioned that “this will help with the chest although they have 10-fold strength difference in available pains.” Of course, this means that the other patient was given dosage forms. Clobazam was approved by Food and Drug the methylphenidate instead of the cardiac drug. It turned out Administration in October 2011 for adjunctive treatment of that the teenager and the other patient had the same name. Lennox-Gaustaut seizures and other epileptic syndromes. Lennox-Gaustaut is a form of childhood-onset epilepsy In the second case, a patient was dispensed amLODIPine, a characterized by frequent seizures and different seizure calcium channel blocker, instead of the anticonvulsant gab- types, often accompanied by developmental delay and apentin.
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Pharmacological Management of Epilepsy
    Epilepsy management ❚ Review Pharmacological management of epilepsy Carole Brown MSc Clin Pharm, MPS, PIP, PwSI epilepsy There have been significant advances in the management of epilepsy since the appearance of bromide in 1857. In the last decade, many new drugs have been developed and general understanding of the condition has improved. Here, Pharmacist Epilepsy Practitioner, Carole Brown, considers the current choice of antiepileptic drugs (AEDs), mode of action, newer AEDS, when to start treatment, epilepsy guidelines, adverse effects of AEDs, generic substitution, therapeutic drug monitoring, driving, contraception and bone health. ong-term antiepileptic drugs (AEDs) remain the main- AEDs exert their effects in a number of ways: Lstay of epilepsy treatment. AEDs eliminate or reduce 1. Modulation of intrinsic membrane conduct- seizure frequency in up to 60–70% of patients.1 Treat- ance, to inhibit excessive firing of neurones, the ment for chronic diseases such as epilepsy means that main targets being sodium and calcium channels, patients often have complex medication regimens to exerting their therapeutic effect by preferential incorporate into their daily routines. AED choice should binding to the inactivated state of the sodium be tailored to individual patient factors that may limit channel, eg phenytoin, lamotrigine and carbamaz- medication use such as tolerability, treatment adherence epine. Kinetics vary, so carbamazepine binds less and side-effect profile. Non-adherence rates among potently but faster than phenytoin. The drugs pre- patients with epilepsy range from 30–50%.2 Clinicians vent the sustained repetitive firing of neurones so treating epilepsy patients note that non-adherent patients prolong the refractory period. Presynaptic pro- report more difficulty in attaining seizure control than teins modulate release of neurotransmitters patients adherent with their medication.
    [Show full text]
  • Calculating Equivalent Doses of Oral Benzodiazepines
    Calculating equivalent doses of oral benzodiazepines Background Benzodiazepines are the most commonly used anxiolytics and hypnotics (1). There are major differences in potency between different benzodiazepines and this difference in potency is important when switching from one benzodiazepine to another (2). Benzodiazepines also differ markedly in the speed in which they are metabolised and eliminated. With repeated daily dosing accumulation occurs and high concentrations can build up in the body (mainly in fatty tissues) (2). The degree of sedation that they induce also varies, making it difficult to determine exact equivalents (3). Answer Advice on benzodiazepine conversion NB: Before using Table 1, read the notes below and the Limitations statement at the end of this document. Switching benzodiazepines may be advantageous for a variety of reasons, e.g. to a drug with a different half-life pre-discontinuation (4) or in the event of non-availability of a specific benzodiazepine. With relatively short-acting benzodiazepines such as alprazolam and lorazepam, it is not possible to achieve a smooth decline in blood and tissue concentrations during benzodiazepine withdrawal. These drugs are eliminated fairly rapidly with the result that concentrations fluctuate with peaks and troughs between each dose. It is necessary to take the tablets several times a day and many people experience a "mini-withdrawal", sometimes a craving, between each dose. For people withdrawing from these potent, short-acting drugs it has been advised that they switch to an equivalent dose of a benzodiazepine with a long half life such as diazepam (5). Diazepam is available as 2mg tablets which can be halved to give 1mg doses.
    [Show full text]
  • Deconstructing Tolerance with Clobazam Post Hoc Analyses from an Open-Label Extension Study
    Deconstructing tolerance with clobazam Post hoc analyses from an open-label extension study Barry E. Gidal, PharmD ABSTRACT Robert T. Wechsler, MD, Objective: To evaluate potential development of tolerance to adjunctive clobazam in patients with PhD Lennox-Gastaut syndrome. Raman Sankar, MD, PhD Methods: Eligible patients enrolled in open-label extension study OV-1004, which continued until Georgia D. Montouris, clobazam was commercially available in the United States or for a maximum of 2 years outside MD the United States. Enrolled patients started at 0.5 mg$kg21$d21 clobazam, not to exceed H. Steve White, PhD 40 mg/d. After 48 hours, dosages could be adjusted up to 2.0 mg$kg21$d21 (maximum 80 mg/d) James C. Cloyd, PharmD on the basis of efficacy and tolerability. Post hoc analyses evaluated mean dosages and drop- Mary Clare Kane, PhD seizure rates for the first 2 years of the open-label extension based on responder categories and Guangbin Peng, MS baseline seizure quartiles in OV-1012. Individual patient listings were reviewed for dosage David M. Tworek, MS, increases $40% and increasing seizure rates. MBA Vivienne Shen, MD, PhD Results: Data from 200 patients were included. For patients free of drop seizures, there was no Jouko Isojarvi, MD, PhD notable change in dosage over 24 months. For responder groups still exhibiting drop seizures, dosages were increased. Weekly drop-seizure rates for 100% and $75% responders demon- strated a consistent response over time. Few patients had a dosage increase $40% associated Correspondence to with an increase in seizure rates. Dr. Gidal: [email protected] Conclusions: Two-year findings suggest that the majority of patients do not develop tolerance to the antiseizure actions of clobazam.
    [Show full text]
  • Drugs of Abuse: Benzodiazepines
    Drugs of Abuse: Benzodiazepines What are Benzodiazepines? Benzodiazepines are central nervous system depressants that produce sedation, induce sleep, relieve anxiety and muscle spasms, and prevent seizures. What is their origin? Benzodiazepines are only legally available through prescription. Many abusers maintain their drug supply by getting prescriptions from several doctors, forging prescriptions, or buying them illicitly. Alprazolam and diazepam are the two most frequently encountered benzodiazepines on the illicit market. Benzodiazepines are What are common street names? depressants legally available Common street names include Benzos and Downers. through prescription. Abuse is associated with What do they look like? adolescents and young The most common benzodiazepines are the prescription drugs ® ® ® ® ® adults who take the drug Valium , Xanax , Halcion , Ativan , and Klonopin . Tolerance can orally or crush it up and develop, although at variable rates and to different degrees. short it to get high. Shorter-acting benzodiazepines used to manage insomnia include estazolam (ProSom®), flurazepam (Dalmane®), temazepam (Restoril®), Benzodiazepines slow down and triazolam (Halcion®). Midazolam (Versed®), a short-acting the central nervous system. benzodiazepine, is utilized for sedation, anxiety, and amnesia in critical Overdose effects include care settings and prior to anesthesia. It is available in the United States shallow respiration, clammy as an injectable preparation and as a syrup (primarily for pediatric skin, dilated pupils, weak patients). and rapid pulse, coma, and possible death. Benzodiazepines with a longer duration of action are utilized to treat insomnia in patients with daytime anxiety. These benzodiazepines include alprazolam (Xanax®), chlordiazepoxide (Librium®), clorazepate (Tranxene®), diazepam (Valium®), halazepam (Paxipam®), lorzepam (Ativan®), oxazepam (Serax®), prazepam (Centrax®), and quazepam (Doral®).
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]
  • Alprazolam: Pediatric Medication
    PATIENT & CAREGIVER EDUCATION Alprazolam This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US ALPRAZolam Intensol; ALPRAZolam XR; Xanax; Xanax XR Brand Names: Canada ALPRAZolam TS; ALPRAZolam-1; APO-Alpraz; APO-Alpraz TS; JAMP-Alprazolam [DSC]; MYLAN-ALPRAZolam [DSC]; NAT-ALPRAZolam [DSC]; RIVA- ALPRAZolam [DSC]; TEVA-Alprazolam; Xanax; Xanax TS Warning This drug is a benzodiazepine. The use of a benzodiazepine drug along with opioid drugs has led to very bad side effects. Side effects that have happened include slowed or trouble breathing and death. Opioid drugs include drugs like codeine, oxycodone, and morphine. Opioid drugs are used to treat pain and some are used to treat cough. Talk with the doctor. If your child is taking this drug with an opioid drug, get medical help right away if your child feels very sleepy or dizzy; if your child has slow, shallow, or trouble breathing; or if your child passes out. Get medical help right away if your child does not respond, does not answer or react like normal, or will not wake up. Benzodiazepines can put your child at risk for addiction, abuse, and misuse. Misuse or abuse of this drug can lead to overdose or death, especially when used along with certain other drugs, alcohol, or street drugs. Addiction can happen even if your child takes this drug as told by the doctor. Get medical Alprazolam 1/9 help right away if your child has changes in mood or behavior, suicidal thoughts or actions, seizures, or trouble breathing.
    [Show full text]
  • Alprazolam (Xanax): Important Patient Information
    What is most important to remember? If you have questions: Strong Internal Medicine • Alprazolam (Xanax®) can be habit-forming and should only be Ask your doctor, nurse or pharmacist for used by the person it was more information about alprazolam prescribed for (Xanax®) • Use this medicine as directed by your doctor • Many times this medicine is ordered to be taken on an as- needed basis. Do not take more often than directed by your doctor • Do not start any new medicines, over-the-counter drugs or herbal remedies without talking to your Strong Internal Medicine doctor 601 Elmwood Avenue th • Tell all doctors, dentists and Ambulatory Care Facility, 5 Floor Rochester, NY 14642 pharmacists that you are using Phone: (585) 275 -7424 alprazolam (Xanax®) Alprazolam Visit our website at: (Xanax®): • Contact your prescriber if your www.urmc.rochester.edu/medicine/ - genera medicine/patientcare/ Important Patient Information symptoms or health problems do l- not get better or are becoming worse What does alprazolam (Xanax®) do? Who should know I am taking alprazolam (Xanax®)? What are some things that I need to be aware of when • It is used to treat symptoms of anxiety • Keep a list of all your medicines (prescription, natural taking alprazolam (Xanax®)? • It is used to treat panic attacks products, supplements, vitamins, over-the-counter) and • Tell your doctor or pharmacist if you are allergic to give it to your healthcare provider (doctor, nurse, nurse alprazolam (Xanax®), or if you are allergic to any other How should alprazolam (Xanax®) be used? practitioner, pharmacist, or physician assistant) medicines, foods, or substances • Use this medicine as directed by your doctor Are there any interactions with other drugs that I need • Before using this medicine, tell your doctor if you have • Many times this medicine is ordered to be taken on an to worry about? glaucoma, liver disease, or lung disease as-needed basis • There are many drug interactions that may increase • This medicine is a controlled substance and may be • Take with or without food.
    [Show full text]